Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and to treat colitis.

In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus (S.) CRL807:CAT, S. thermophilus CRL807: SOD, Lactococcus (L.) lactis NCDO2118 pXILCYT:IL-10, L. lactis MG1363 pValac:IL-10 and L. lactis MG1363 pGroESL:IL-10 with proven beneficial effects were compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of genetically modified strains evaluated in the present work showed that they were just as safe as the administration of the native strains from which they derive as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation, altered blood parameters and modifications of intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients suffering IBD. PMID: 27469354 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research